Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

Hypertension

Volumn 46, Issue 3, 2005, Pages 469-470

  Warnock, David G ^a,b   Bell, P Darwin ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; PLACEBO; RENIN; SODIUM CHANNEL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DNA POLYMORPHISM; EDITORIAL; HUMAN; HYPERKALEMIA; HYPERTENSION; LIDDLE SYNDROME; MUTATION; NEGRO; NEPHRON; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE; SODIUM TRANSPORT;

AFRICAN AMERICANS; ALDOSTERONE ANTAGONISTS; AMILORIDE; BLOOD PRESSURE; DIURETICS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPITHELIAL SODIUM CHANNEL; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 25444532570     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000179583.64413.c1     Document Type: Editorial

References (19)

1. Rossier BC. 1996 Homer Smith Award Lecture. Cum grano salis: the epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol. 1997;8:980-992.
2. Meneton P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive distal nephron: the pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol. 2005;287:F593-F601.
3. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972; 52:584-594.
4. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, Canessa CM, Rossier BC, Liifton RP. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407-414.
5. Warnock DG. Low-renin and nonmodulating essential hypertension. Hypertension. 1999;34:395-397.
6. Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinla AK, Markandu ND, Cappuccio FP, Cook DG, Persu A, Corvol P, Jeunemaitre X, Carter ND, MacGregor GA. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet. 1998;351:1388-1392.
7. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, MacGregor GA. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. 2002;40:3-17.
8. Saha C, Eckert GJ, Ambrosius WT, Chun T-Y, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46: xx-xx.
9. Pratt JH, Ambrosius WT, Agarwal R, Eckert GJ, Newman S. Racial difference in the activity of the amiloride-sensitive epithelial sodium channel. Hypertension. 2002;40:903-908.
10. Campia U, Cardillo C, Panza JA. Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation. 2004;109:3191-3195.
11. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension. 2004;43:36-40.
12. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
13. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109: 2857-2861.
14. Bull MB, Laragh JH. Amiloride. A potassium-sparing natriuretic agent. Circulation. 1968;37:45-53.
15. Keim HJ, Drayer JI, Thurston H, Laragh JH. Triamterene-induced changes in aldosterone and renin values in essential hypertension. Evidence of a role for aldosterone in preventing blood pressure reduction. Arch Intern Med. 1976;136:645-648.
16. Endemann D, Marienhagen J, Stubanus M, Luger RJ, Fischereder M, Riegger GA, Kramer BK. Volume independent stimulation of renin secretion by a single dose of amiloride in man. Arzneimittelforschung. 2002;52:677-683.
17. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
18. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585-592.
19. Page GP, George V, Go RC, Page PZ, Allison DB. "Are we there yet?" Deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am J Hum Genet. 2003;73: 711-719.